Ashland to expand bioresorbable polymers capacity in Ireland

The capital expansion program commenced in June 2022 and is expected to complete in 2024

Stelis Biopharma’s flagship facility receives EIR from USFDA

The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise

Cipla (EU) to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical

Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.

Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US

This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US

SciGenom announces Phd program in collaboration with CHARUSAT University

This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists

Cipla receives 6 observations from USFDA for Goa facility

There are no data integrity (DI) observations.

Lupin launches Desvenlafaxine extended-release tablets in the US

Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V.

Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada

With the receipt of the EIR, the inspection stands successfully closed.

US FDA inspection at Gland Pharma's Dundigal facility, Hyderabad

The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.

Lupin and I'rom signs licensing agreement for Denosumab biosimilar for Japan